Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant. Antidepressants in general have been examined for treatment of depression in patients with cancer. Duloxetine specifically has been examined for its effect on pain and peripheral neuropathy.
Effectiveness Not Established
Research Evidence Summaries
Matsuoka, H., Makimura, C., Koyama, A., Otsuka, M., Okamoto, W., Fujisaka, Y., . . . Nakagawa, K. (2012). Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. Anticancer Research, 32,1805–1809.http://ar.iiarjournals.org/content/32/5/1805.abstract
To investigate the effect of duloxetine for cancer-related neuropathic pain in patients for whom treatment with pregabalin was unsuccessful
Intervention Characteristics/Basic Study Process:
Data were retrospectively reviewed for patients experiencing neuropathic pain who were treated with duloxetine because pregabalin could not be administered, was ineffective, or where the dosage could not be increased due to side effects. Patients were given 20 mg of duloxetine per day, increased to 40 mg/day if needed. Pain was assessed for two weeks.
- The study reported on a sample of 15 patients.
- Patient age range was 31–79 years.
- The sample was 60% male and 40% female.
- Cancer diagnoses included breast, colon, and lung.
- Most patients were also receiving strong opioids.
- Single site
- Outpatient setting
A retrospective study design was used.
Numeric rating scale for pain
Pain was reduced in 7 of the 15 patients. Baseline pain ranged from 5 to 10. After two to four weeks, pain ratings ranged from 2 to 9.
Duloxetine may be effective for relief of neuropathic pain.
- The study has a small sample, with less than 30 participants.
- The study has risk of bias due to no control group, no blinding, and no random assignment.
- There was no magnitude analysis of individual pain rating changes.
- There was no discussion of opioid dose changes, or any use of breakthrough medications.
- It appears that pain rating was done at a single time point per week; it is not clear whether this was self-report or of average, current, or worst pain.
Findings suggest that duloxetine may be helpful for patients with neuropathic pain as an alternative to pregabalin. This study provides weak evidence due to multiple study limitations. Further well-designed research is needed to identify the most effective management for cancer-related neuropathic pain.